AMNEAL PHARMACEUTICALS INC (AMRX) Fundamental Analysis & Valuation

NASDAQ:AMRX • US03168L1052

13.24 USD
-0.02 (-0.15%)
At close: Mar 6, 2026
13.24 USD
0 (0%)
After Hours: 3/6/2026, 8:00:39 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This AMRX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

5

Overall AMRX gets a fundamental rating of 5 out of 10. We evaluated AMRX against 193 industry peers in the Pharmaceuticals industry. AMRX scores excellent on profitability, but there are some minor concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on AMRX.


Dividend Valuation Growth Profitability Health

7

1. AMRX Profitability Analysis

1.1 Basic Checks

  • In the past year AMRX was profitable.
  • AMRX had a positive operating cash flow in the past year.
  • In multiple years AMRX reported negative net income over the last 5 years.
  • AMRX had a positive operating cash flow in each of the past 5 years.
AMRX Yearly Net Income VS EBIT VS OCF VS FCFAMRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M -400M

1.2 Ratios

  • AMRX has a better Return On Assets (1.96%) than 82.38% of its industry peers.
  • AMRX has a Return On Invested Capital of 11.24%. This is amongst the best in the industry. AMRX outperforms 90.16% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for AMRX is below the industry average of 13.00%.
  • The 3 year average ROIC (10.04%) for AMRX is below the current ROIC(11.24%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 1.96%
ROE N/A
ROIC 11.24%
ROA(3y)-1.27%
ROA(5y)-1.39%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)10.04%
ROIC(5y)8.08%
AMRX Yearly ROA, ROE, ROICAMRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100 -100 -200 -300 -400

1.3 Margins

  • AMRX has a Profit Margin of 2.39%. This is amongst the best in the industry. AMRX outperforms 80.83% of its industry peers.
  • AMRX's Profit Margin has declined in the last couple of years.
  • AMRX's Operating Margin of 13.18% is amongst the best of the industry. AMRX outperforms 86.01% of its industry peers.
  • AMRX's Operating Margin has improved in the last couple of years.
  • AMRX has a Gross Margin of 36.88%. This is in the better half of the industry: AMRX outperforms 60.62% of its industry peers.
  • AMRX's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 13.18%
PM (TTM) 2.39%
GM 36.88%
OM growth 3Y13.53%
OM growth 5Y12.51%
PM growth 3YN/A
PM growth 5Y-12.19%
GM growth 3Y0.83%
GM growth 5Y2.08%
AMRX Yearly Profit, Operating, Gross MarginsAMRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 -60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. AMRX Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so AMRX is still creating some value.
  • The number of shares outstanding for AMRX has been increased compared to 1 year ago.
  • Compared to 5 years ago, AMRX has more shares outstanding
  • The debt/assets ratio for AMRX has been reduced compared to a year ago.
AMRX Yearly Shares OutstandingAMRX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M
AMRX Yearly Total Debt VS Total AssetsAMRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

2.2 Solvency

  • AMRX has an Altman-Z score of 1.98. This is not the best score and indicates that AMRX is in the grey zone with still only limited risk for bankruptcy at the moment.
  • AMRX has a better Altman-Z score (1.98) than 63.21% of its industry peers.
  • AMRX has a debt to FCF ratio of 11.66. This is a negative value and a sign of low solvency as AMRX would need 11.66 years to pay back of all of its debts.
  • AMRX has a Debt to FCF ratio of 11.66. This is in the better half of the industry: AMRX outperforms 79.79% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 11.66
Altman-Z 1.98
ROIC/WACC1.17
WACC9.64%
AMRX Yearly LT Debt VS Equity VS FCFAMRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B 2B 2.5B

2.3 Liquidity

  • AMRX has a Current Ratio of 2.17. This indicates that AMRX is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 2.17, AMRX perfoms like the industry average, outperforming 41.45% of the companies in the same industry.
  • A Quick Ratio of 1.48 indicates that AMRX should not have too much problems paying its short term obligations.
  • AMRX has a Quick ratio of 1.48. This is in the lower half of the industry: AMRX underperforms 61.66% of its industry peers.
Industry RankSector Rank
Current Ratio 2.17
Quick Ratio 1.48
AMRX Yearly Current Assets VS Current LiabilitesAMRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. AMRX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 44.83% over the past year.
  • Measured over the past 5 years, AMRX shows a small growth in Earnings Per Share. The EPS has been growing by 5.92% on average per year.
  • AMRX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 8.05%.
  • Measured over the past years, AMRX shows a quite strong growth in Revenue. The Revenue has been growing by 8.66% on average per year.
EPS 1Y (TTM)44.83%
EPS 3Y7.3%
EPS 5Y5.92%
EPS Q2Q%75%
Revenue 1Y (TTM)8.05%
Revenue growth 3Y10.92%
Revenue growth 5Y8.66%
Sales Q2Q%11.47%

3.2 Future

  • Based on estimates for the next years, AMRX will show a small growth in Earnings Per Share. The EPS will grow by 5.77% on average per year.
  • The Revenue is expected to decrease by -0.46% on average over the next years.
EPS Next Y16.11%
EPS Next 2Y18.48%
EPS Next 3Y17.57%
EPS Next 5Y5.77%
Revenue Next Year3.71%
Revenue Next 2Y5.25%
Revenue Next 3Y5.18%
Revenue Next 5Y-0.46%

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
AMRX Yearly Revenue VS EstimatesAMRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1B 2B 3B
AMRX Yearly EPS VS EstimatesAMRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0.5 1

More info and screens

Find the best growth stocksShow best growing peers

7

4. AMRX Valuation Analysis

4.1 Price/Earnings Ratio

  • AMRX is valuated correctly with a Price/Earnings ratio of 15.76.
  • Compared to the rest of the industry, the Price/Earnings ratio of AMRX indicates a rather cheap valuation: AMRX is cheaper than 86.53% of the companies listed in the same industry.
  • When comparing the Price/Earnings ratio of AMRX to the average of the S&P500 Index (26.29), we can say AMRX is valued slightly cheaper.
  • With a Price/Forward Earnings ratio of 13.57, AMRX is valued correctly.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of AMRX indicates a rather cheap valuation: AMRX is cheaper than 85.49% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 24.57. AMRX is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 15.76
Fwd PE 13.57
AMRX Price Earnings VS Forward Price EarningsAMRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, AMRX is valued cheaper than 88.08% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of AMRX indicates a rather cheap valuation: AMRX is cheaper than 86.01% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 18.46
EV/EBITDA 10.49
AMRX Per share dataAMRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

  • AMRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • AMRX has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as AMRX's earnings are expected to grow with 17.57% in the coming years.
PEG (NY)0.98
PEG (5Y)2.66
EPS Next 2Y18.48%
EPS Next 3Y17.57%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AMRX Dividend Analysis

5.1 Amount

  • No dividends for AMRX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AMRX Fundamentals: All Metrics, Ratios and Statistics

AMNEAL PHARMACEUTICALS INC

NASDAQ:AMRX (3/6/2026, 8:00:39 PM)

After market: 13.24 0 (0%)

13.24

-0.02 (-0.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-27
Earnings (Next)04-30
Inst Owners45.17%
Inst Owner Change-0.48%
Ins Owners46.29%
Ins Owner Change-0.21%
Market Cap4.17B
Revenue(TTM)3.02B
Net Income(TTM)72.06M
Analysts81.82
Price Target14.79 (11.71%)
Short Float %6.79%
Short Ratio4.01
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.37%
Min EPS beat(2)11.53%
Max EPS beat(2)21.21%
EPS beat(4)4
Avg EPS beat(4)28.29%
Min EPS beat(4)11.53%
Max EPS beat(4)40.37%
EPS beat(8)7
Avg EPS beat(8)21.12%
EPS beat(12)11
Avg EPS beat(12)30.53%
EPS beat(16)12
Avg EPS beat(16)21.16%
Revenue beat(2)0
Avg Revenue beat(2)-0.8%
Min Revenue beat(2)-1.18%
Max Revenue beat(2)-0.41%
Revenue beat(4)0
Avg Revenue beat(4)-2.73%
Min Revenue beat(4)-4.71%
Max Revenue beat(4)-0.41%
Revenue beat(8)3
Avg Revenue beat(8)-0.24%
Revenue beat(12)6
Avg Revenue beat(12)0.1%
Revenue beat(16)8
Avg Revenue beat(16)-0.09%
PT rev (1m)0%
PT rev (3m)8.75%
EPS NQ rev (1m)2.21%
EPS NQ rev (3m)2.56%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.24%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.03%
Revenue NY rev (1m)0.03%
Revenue NY rev (3m)0.03%
Valuation
Industry RankSector Rank
PE 15.76
Fwd PE 13.57
P/S 1.38
P/FCF 18.46
P/OCF 12.25
P/B N/A
P/tB N/A
EV/EBITDA 10.49
EPS(TTM)0.84
EY6.34%
EPS(NY)0.98
Fwd EY7.37%
FCF(TTM)0.72
FCFY5.42%
OCF(TTM)1.08
OCFY8.16%
SpS9.59
BVpS-0.23
TBVpS-3.91
PEG (NY)0.98
PEG (5Y)2.66
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 1.96%
ROE N/A
ROCE 14.23%
ROIC 11.24%
ROICexc 12.5%
ROICexgc 23.19%
OM 13.18%
PM (TTM) 2.39%
GM 36.88%
FCFM 7.47%
ROA(3y)-1.27%
ROA(5y)-1.39%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)10.04%
ROIC(5y)8.08%
ROICexc(3y)10.72%
ROICexc(5y)8.59%
ROICexgc(3y)22.54%
ROICexgc(5y)18.52%
ROCE(3y)13.13%
ROCE(5y)10.51%
ROICexgc growth 3Y26.84%
ROICexgc growth 5Y18.51%
ROICexc growth 3Y34.73%
ROICexc growth 5Y26.54%
OM growth 3Y13.53%
OM growth 5Y12.51%
PM growth 3YN/A
PM growth 5Y-12.19%
GM growth 3Y0.83%
GM growth 5Y2.08%
F-Score7
Asset Turnover0.82
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 11.66
Debt/EBITDA 4.22
Cap/Depr 51.15%
Cap/Sales 3.79%
Interest Coverage 2.01
Cash Conversion 54.71%
Profit Quality 313.13%
Current Ratio 2.17
Quick Ratio 1.48
Altman-Z 1.98
F-Score7
WACC9.64%
ROIC/WACC1.17
Cap/Depr(3y)37.69%
Cap/Depr(5y)34.67%
Cap/Sales(3y)3.12%
Cap/Sales(5y)3.19%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.83%
EPS 3Y7.3%
EPS 5Y5.92%
EPS Q2Q%75%
EPS Next Y16.11%
EPS Next 2Y18.48%
EPS Next 3Y17.57%
EPS Next 5Y5.77%
Revenue 1Y (TTM)8.05%
Revenue growth 3Y10.92%
Revenue growth 5Y8.66%
Sales Q2Q%11.47%
Revenue Next Year3.71%
Revenue Next 2Y5.25%
Revenue Next 3Y5.18%
Revenue Next 5Y-0.46%
EBIT growth 1Y14.22%
EBIT growth 3Y25.92%
EBIT growth 5Y22.25%
EBIT Next Year19.49%
EBIT Next 3Y13.5%
EBIT Next 5Y4.21%
FCF growth 1Y2.51%
FCF growth 3YN/A
FCF growth 5Y-6.32%
OCF growth 1Y15.21%
OCF growth 3Y73.5%
OCF growth 5Y-2.15%

AMNEAL PHARMACEUTICALS INC / AMRX FAQ

What is the fundamental rating for AMRX stock?

ChartMill assigns a fundamental rating of 5 / 10 to AMRX.


What is the valuation status for AMRX stock?

ChartMill assigns a valuation rating of 7 / 10 to AMNEAL PHARMACEUTICALS INC (AMRX). This can be considered as Undervalued.


How profitable is AMNEAL PHARMACEUTICALS INC (AMRX) stock?

AMNEAL PHARMACEUTICALS INC (AMRX) has a profitability rating of 7 / 10.


How financially healthy is AMNEAL PHARMACEUTICALS INC?

The financial health rating of AMNEAL PHARMACEUTICALS INC (AMRX) is 4 / 10.


Can you provide the expected EPS growth for AMRX stock?

The Earnings per Share (EPS) of AMNEAL PHARMACEUTICALS INC (AMRX) is expected to grow by 16.11% in the next year.